Építés alatt – nem éles oldal
Belépés
VisszavonvaFázis nélkül

SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty

A legfontosabb adatok

Ki végzi
Stanford University
Hol
Stanford (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Kezdés
2024. jún.
Várható befejezés
2026. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Active TBS-DLPFC
  • Sham TBS-DLPFC
  • Open label TBS-DLPFC
A regiszteradat frissítve
2022. december 14.
Miért állt le
Logistical constraints

Ki vehet részt

Életkor
22 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (39)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Male or female, 22 to 80 years of age
  • Able to provide informed consent
  • Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE)
  • Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy. Participants may choose to not be on antidepressant therapy for the study duration, or to be switched from other classes to a medication from the SSRI class
  • Participants may also have a history of intolerance to at least 2 antidepressant medications. These patients with the intolerance history will not be required to be currently taking an antidepressant medication
  • Participants must qualify as "Moderately Treatment Refractory" or "High Treatment Refractory" using the Maudsley staging method
  • Meet the threshold on the total HAMD17 score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
  • Meet the threshold on the total MADRS score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
  • Meet the threshold on the total BDI-II score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0)
  • In good general health, as ascertained by medical history
  • If female, a status of non-childbearing potential or use of an acceptable form of birth control. The form of birth control will be documented at screening and baseline
  • Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable

Ki nem vehet részt

  • Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence, at screening or within six months prior to screening
  • History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes
  • Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening
  • Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation
  • Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more)
  • Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation
  • History of positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates
  • History of epilepsy
  • History of rTMS exposure
  • History of any implanted device or psychosurgery for depression
  • History of ECT intolerance
  • History of shrapnel or metal in the head or skull
  • History of cardiovascular disease or cardiac event
  • History of OCD
  • History of autism spectrum disorder
  • History of intractable migraine
  • History of independent sleep disorder
  • Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study
  • Female that is pregnant or breastfeeding
  • Female with a positive pregnancy test at participation
  • Total HAMD17 score of < 20 at the screen or baseline visits
  • Total MADRS score of < 20 at the screen or baseline visits
  • Total BDI-II score of < 20 at the screen or baseline visits
  • Considered at significant risk for suicide during the course of the study
  • Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results
  • Current (or chronic) use of opiates
  • "Low Treatment Refractory" using the Maudsley staging method

Helyszínek itt: Egyesült Államok

  • Department of Psychiatry and Behavioral Sciences, Stanford School of MedicineStanford, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.

A vizsgálat 2 csoportja

  • Active TBS-DLPFCA vizsgált kezelés

    The active group will receive theta-burst TMS stimulation.

  • Sham TBS-DLPFCSzínlelt kezelés, összehasonlításként

    The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.

    Kezelés: Sham TBS-DLPFC és Open label TBS-DLPFC

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Accelerated Intermittent Theta-burst Stimulation for Treatment of Preoperative Depression to Reduce Conversion of Acute to Chronic Opioid Use Following Arthroplasty
A regiszteradat frissítve
2022. december 14.